Fidia's Hyalgan osteoarthritis injection U.S. launch to be backed by Sanofi, OrthoLogic direct reps.
This article was originally published in The Gray Sheet
Executive Summary
FIDIA'S HYALGAN TO BE BACKED BY 415-REP U.S. SALES FORCE in a market introduction of the hyaluronic acid-based knee joint injection product planned for July. Under an exclusive U.S. licensing deal announced June 25, Sanofi Pharmaceuticals will offer the product through 250 reps to rheumatologists, family practice physicians and others who treat osteoarthritis except for orthopedic surgeons. A separate co-promotion agreement between Sanofi and OrthoLogic will provide an additional 165 reps targeting orthopedic surgeons.